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 Calling for global standardization in cosmetic testing
may appear appealing, but could it be merely the revival of  the
quest for the Holy Grail? Dr Roberts’ plea merits some reflection.
First of  all, in order to avoid confusion and unrealistic
aspirations in cosmetology one should clearly distinguish









It is also important to define the people whose priorities should
be met. Is standardization needed by the cosmetic industry, by
research centre facilities, by contract research organizations, by
regulatory authorities or by consumers? The variable aims,
thresholds of  technical know-how, and knowledge in relevant
skin physiology and biology among intervening parties may
indeed decipher the issue. These concerns are discussed
hereafter.
I fully agree with Dr Roberts that testing should be performed
in a standardized way whenever possible to predict tolerance
and safety of  cosmetics. The rules edicted by toxicology should
be strictly applied. As indicated in her document, testing for
chemical ingredients can currently be performed using labora-
tory animals. However, it must be stressed that this situation is
no longer acceptable for proprietary cosmetic formulations that
are brought to the market. Methods that avoid animal testing
have been used in this field for many years.
I disagree with many of  the contentions made by Dr Roberts
about cosmetic efficacy testing. Indeed, I found what appear to
be contradictions and misperceptions in her statements. In the
field of  dermatology there is little standardization in assessing
drug efficacy. Similarly, cosmetology, which is constantly evolv-
ing, has also escaped rigid scrutiny of  its wide varying claims.
In these respects, proficiency and internal quality controls are
awaited from test centres. Standards are also expected to be met
by commercial instrumental devices. Beyond these controlled
procedures standards can hardly be proposed to calibrate
human physiology and any cosmetic effect modifying it. I
suspect that their introduction would not result in improving
product efficacy, but rather would curb innovations and original
thought.
During the past two decades staggering advances have been
made in many areas of  cosmetic science. The field of  objective
efficacy evaluations has created a rapid flow of  publications.
Although much remains to be done, the pace of  scientific discov-
eries and technical developments has been rapid and appears to
be accelerating. These advances have also been accompanied by
setbacks, notably inconsistencies in technical procedures and
disparate data interpretations used to support efficacy claims. In
these respects, distinct guidelines in efficacy testing have been
proposed independently by Colipa and the EEMCO group. They
highlight the steps necessary for rigorous experiments and for
clear interpretation of  data. The allegation made by Dr Roberts
about the EEMCO publications is particularly misleading.
Indeed, in all instances, EEMCO has stressed the importance of
robust scientific work supported by accurate statistical analysis.
In addition, EEMCO, and many other researchers, are convinced
that any specific and objective measurement only provides
information about a restricted aspect of  global cosmetic efficacy.
A thorough assessment is most often encouraged, even though
it has limits, as many variables cannot be controlled adequately.
The case of  sun protection factors (SPF) presented by Dr Roberts
reveals a contradiction in her plea. This is a unique standardized
procedure for efficacy testing; its relevance is repeatedly dis-
puted. As a result, Dr Roberts cites it as an example of  a ‘stand-
ard test which needs to evolve with time’. This statement
illustrates how standardization can be advocated and rejected
in the same sentence. It also shows a diversity of  expectations of
a magic ‘standardization’ by different individuals. Indeed, SPF
is only indicative of  comparative efficacy against UV-induced
erythema. It cannot cope with the interindividual physiological
variability among subjects, even of  the same phototype. It is
clear that interlaboratory differences are important and also
work against standardization applied in this field. Furthermore,
erythema-driven SPF cannot be extrapolated as an indisputable
predictor for UV-induced immunosuppression and UV-induced
carcinogenesis. In short, both experts and laypeople must be
aware that ‘a controlled laboratory situation is a far cry from
general slapping on of  sunscreen on the beach …’. Revisiting
SPF standardization would be a huge and highly controversial
topic! I am also less enthusiastic than Dr Roberts with regards
to the Boots star rating system for assessing UVA protection.
This approach has an attractive marketing appeal, but I do not
perceive any underlying robust scientific background to it. I
rather prefer the assessment of  the ‘persistent pigment darken-
ing’ method as used in Japan, or any other similar objective
evaluation. However, for many diverse reasons there are oppon-
ents to such measurements and I am quite sure that any stand-
ardized method whatsoever would attract a round of  confusing
detractors. In short, in some branches of  dermocosmetology,
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efficacy assessments do not benefit from indisputable norms.
Skin physiology is so diverse in its facets, and so variable and
sometimes unpredictable among individuals that it precludes
any simple cookbook rule of  evaluation. As a result, there is
currently no definite and definitive link between standardiza-
tion, scientific consensus and progress in cosmetology. This
situation is unfortunate, however I do not foresee any improve-
ment on the horizon. Nevertheless, the pace of  change is nowhere
quicker than in technology and biology. One day, certainly, a
breakthrough will come in the controversial area of  rating
cosmetic efficacy. To remain realistic today, count whenever
possible, measure when you can, and if  there is no measure-
ment, invent one. However, with the help of, or in spite of, ideas
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 Despite the length of  his reply and our
differing backgrounds, I suspect we share many of  the same
views and objectives.
We both share the view that our primary interest is the con-
sumer. We both aspire to the best possible quality in cosmeto-
logy, as in science in general, especially when concerning safety
or efficacy. It is precisely because of  the variability in human
physiology that I believe we should standardize other variables
as much as possible.
I shall reply to specific points raised by Professor Piérard,
where I suspect originally I may not have made myself  clear.
Firstly, I apologise if  my reference to the European Expert
Group on Efficacy Measurement of  Cosmetics and Other Topical




 It was a quotation from
Professor Piérard’s guest editorial in the June 2000 edition of
the International Journal of  Cosmetic Science, Volume 22,
Number 3, Pages 163–166, entitled: ‘EEMCO onward and
upward. Streamlining its endeavour at the European venture in
cosmetic efficacy testing.’ The full quotation is: ‘We are well
aware that standardization of  procedures may erode experi-
mental freedom and lead to ‘cookbook practice’. By contrast,
EEMCO guidance will continue to respect creativity and the
obligation to think and to place the needs of  the consumer first.’
I hope this clarifies matters.
Secondly, my reference to the Boots UVA star rating sys-
tem was not a personal endorsement of  this method over
others. I merely intended to point out that the imposition of
a standard, in particular one that could convey a marketing
advantage, had the effect of  rapidly improving the quality of
UVA protection afforded by sunscreens marketed in the UK.
Prompted by Professor Piérard’s response, however, I would
rather not see another UV measurement standard that involves
irradiating volunteers with relatively large doses of  UV at high
intensity.
Finally, I agree that revisiting sun protection factor (SPF)
standardization would be a huge and controversial topic.
Nevertheless we should not bury our heads in the sand and
wish it had never happened. I was never a fan of  sun protec-
tion by numbers but, at least when products achieved relat-
ively low SPF values, the method was able to measure SPF with
reasonable accuracy. The very high UV protection possible
with modern sunscreens is beyond the reliability of  the method
and this is why I suggested that it needed to evolve. It would be
preferable to temper the labelling within the range of  accuracy
of  the existing method. I appreciate that SPF measurement
based on an erythema action spectrum may not predict UV-
induced immunosuppression or carcinogenesis but it has
driven the development of  more effective sunscreens.
Standardization may well be an unrealistic aspiration,
whether it relates to safety or efficacy. It certainly is not the easy
option, given the political machinery that would have to be












































  as an apology,
or as evidence of  personal development, but as a clarification of
our position. We are, however, delighted that Professor Marks
appears to share our view about the sun exposure behaviour
that should be encouraged and the need to communicate this
information openly and honestly. We still believe that the basis
for current advice to reduce exposure to sunlight should be
reviewed in a formal and quantitative manner. The challenge
will then be to regain the public’s trust by correcting the
misleading messages that have been promulgated in health
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agree that moderation in sun exposure is indeed the appropriate
approach. This is the same approach as mine and, I believe, that
of  the majority of  dermatologists, at least as far as fair-skinned
subjects are concerned. Dark-skinned people are essentially not
at risk from sunlight-induced cancers, although they are still
clearly subject to sunlight-induced skin ageing, as demonstrated
by dark-skinned elderly folk who live in tropical climes.
Nevertheless, Ness and his co-authors still do not seem to rec-
ognize that there are differences between exposure to sunlight’s
ultraviolet (UV) radiation on the one hand and to its warmth
and visible light on the other. UV is present in the middle of  the
day (broadly speaking between about 10.30 am and 3.30 pm)
in summer, and throughout the year in tropical latitudes. It is
not UV that makes us feel good. The only components which do








. yet state that only small amounts of  sun exposure to small
areas of  the body (say for about 5–10 min to face and hands,
twice or three times a week) are enough to maintain vitamin D
levels in fair skinned subjects (who are of  course the subjects at
risk of  skin cancer) and that this is easy to achieve without sun-





The advice to fair-skinned sun exposers should be to take care
in the middle of  the day in summer and on sunny vacations but
to enjoy the feel good factors of  (1) the usually pleasant appear-
ance of  the sun’s rays falling on our surroundings; (2) the mood-
elevating effect of  sun’s visible light operating through our eyes,
and (3) the sun’s warmth. We will then not suffer sunburn, skin
cancers or the eventual ubiquitous photoageing (all of  which
makes us look and feel bad, the latter often by being associated
with dry, itchy skin).
So take care in the middle of  the day in summer and on sunny
vacations, even on cloudy or cool days, by seeking the shade,
covering up or wearing copious sunscreen. Enjoy the sun at
other times. Otherwise, many non-fatal skin cancers, itchy,
unpleasant old-looking skin and relatively uncommon but fatal
skin cancers will all continue to occur. From what I can assess




 however, they would now
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 Vitiligo causes significant cosmetic disability in dark
skinned populations. This is reflected in Omar Quayyam’s
poignant remark – ‘A black spot on a white skin may be a





search for an effective treatment for vitiligo continues, different
surgical methods such as split thickness Thierch graft, punch
graft, suction blister graft, etc. have been tried in recent years, to














 and spot chemabrasion by the use of  chemical




 These latter methods
depend on the stimulation of  follicular melanocytes with in the





an agent used to achieve medium depth to deep chemical
peeling of  face, is known to cause post inflammatory pigmen-
tation as a complication in dark-skinned patients. Use of  phenol
in vitiligo has not been previously reported and we describe
successful use of  phenol to achieve pigmentation in vitiligo.
We use absolute phenol for this purpose. The preparation of
the patient is essentially the same as in any phenol peel or
chemical cautery. Informed consent should be obtained. The
procedure should not be used in patients with a tendency
towards keloids.
Phenol is applied lightly with a cotton stick applicator over
the lesion, until a uniform frost is achieved. The patient may
experience a mild burning sensation and discomfort, which is
usually well-tolerated. Care should be exercised to prevent
phenol streaming on to the surrounding skin.
The lesion undergoes erythema (Fig. 1) over the next 2–
3 days, subsiding in 7–10 days. Mild scaling may result. Emol-
lients may be prescribed at this stage. Hydrocortisone ointment
may be used if  erythema is severe.
The erythema is followed by rapid perifolllicular pigmenta-
tion within the lesion and a uniform pigmentation at the
borders of  the lesion, over 2–3 weeks (Fig. 2) The pigmentation
is usually darker than the surrounding skin, however this is
acceptable to our patients. The pigmentation can be further
enhanced with the use of  PUVA therapy after this period. The
procedure can also be repeated after an interval of  6–8 weeks.
We do not recommend using this procedure on the face, as it
may be difficult to achieve uniform, cosmetically acceptable
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pigmentation. So far we have used the procedure in 10 patients
and have found it to be very useful as it is easy, safe, and pro-
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Figure 1 Vitiligo lesion over elbow, one week after phenolization, 
showing erythema.
Figure 2 Lesion three weeks after phenolization, showing spotty 
pigmentation.
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